Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

EdClinical
clinicalleader.com > doc > what-briacell-s-trial-design-says-about-real-world-cancer-research-0001

What BriaCell's Trial Design Says About Real-World Cancer Research

1+ hour, 31+ min ago   (603+ words) Guest Column | August 24, 2026 A conversation between BriaCell President and CEO William Williams, MD, FACP, and Clinical Leader Executive Editor Abby Proch Developing a last-line cancer treatment is a complex space to occupy — as stressful and high stakes as it is…...

EdClinical
clinicalleader.com > doc > ways-that-ai-and-point-of-care-diagnostics-are-redefining-clinical-trial-design-and-operations-0001

4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations

1+ hour, 31+ min ago   (370+ words) Guest Column | August 24, 2026 By Partha Anbil and Deepak Manjrekar A primary challenge in clinical research has always been patient recruitment and enrollment. Historically, identifying eligible patients, particularly for complex trials with stringent inclusion and exclusion criteria, required manual chart reviews…...

EdClinical
clinicalleader.com > doc > sustainable-patient-engagement-your-enrollment-and-representation-depend-on-it-0001

Sustainable Patient Engagement: Your Enrollment And Representation Depend On It

3+ day, 1+ hour ago   (392+ words) Guest Column | August 21, 2026 A conversation between Boehringer Ingelheim Head Of U.S. Clinical Development Operations Karen Correa, Ph.D., and Clinical Leader Executive Editor Abby Proch If you’re looking for community engagement to be the salve for lagging patient enrollment, you’re already too…...

EdClinical
clinicalleader.com > doc > building-the-execution-architecture-for-real-world-data-to-have-real-world-impact-0001

Building The Execution Architecture For Real-World Data To Have Real-World Impact

4+ day, 1+ hour ago   (717+ words) Guest Column | August 20, 2026 By Steven C. Grambow, Drew Narayan, Steve Frank, Norm Goldberg, Gwyn Cready, and Hayden B. Bosworth We further introduce a maturity model in which organizations must develop both analytical capability and execution capability. Organizations that invest in only one…...

EdClinical
clinicalleader.com > doc > rare-disease-study-gets-a-boost-from-crowdsourced-patient-reported-data-0001

Rare Disease Study Gets A Boost From Crowdsourced Patient Reported Data

6+ day, 1+ hour ago   (385+ words) Guest Column | August 18, 2026 A conversation between Jen A. Levitt, MD, and Clinical Leader Executive Editor Abby Proch In this interview, Jen A. Levitt, MD, Department of Dermatology at Emek Medical Center in Israel, talks about her team’s recent Hailey‑Hailey disease study,…...

Google News
clinicalleader.com > doc > the-patient-advocacy-strategy-behind-skyhawk-s-rapid-enrollment-0001

The Patient Advocacy Strategy Behind Skyhawk's Rapid Enrollment

1+ week, 4+ day ago   (1179+ words) Guest Column | August 13, 2026 A conversation with Skyhawk Therapeutics and Clinical Leader Executive Editor Abby Proch It’s not every day you get a group of clinical research professionals eagerly chiming in on their recent trial success. But it’s really not that…...

EdClinical
clinicalleader.com > doc > what-the-fda-s-latest-move-on-psychedelics-means-for-non-hallucinogenic-drug-sponsors-0001

What The FDA's Latest Move On Psychedelics Means For Non-Hallucinogenic Drug Sponsors

1+ week, 4+ day ago   (741+ words) Guest Column | August 13, 2026 A conversation between Enveric Biosciences CEO Joseph Tucker, Ph.D., and Clinical Leader Executive Editor Abby Proch The steady progress and openness in this regard is not lost on Joseph Tucker, Ph.D., CEO of Enveric Biosciences, which is…...

EdClinical
clinicalleader.com > doc > what-fda-s-psychedelic-drug-focus-means-for-classic-psychedelic-development-0001

What FDA's Psychedelic Drug Focus Means For Classic Psychedelic Development

1+ week, 4+ day ago   (611+ words) Guest Column | August 13, 2026 A conversation between Psychedelic Alpha Founder Josh Hardman and Clinical Leader Executive Editor Abby Proch With an addition to its website — a psychedelic resource page — it seems the FDA is increasingly interested in psychedelic drug development. But…...

EdClinical
clinicalleader.com > doc > the-renaissance-of-psychedelic-research-history-protocols-and-forward-trajectories-0001

The Renaissance Of Psychedelic Research: History, Protocols, And Forward Trajectories

1+ week, 4+ day ago   (189+ words) Clinical Leader The Renaissance Of Psychedelic Research: History, Protocols, And Forward Trajectories The resurgence of psychedelic research marks a dramatic shift in modern psychiatry. Long restricted by regulatory barriers, compounds like psilocybin, MDMA, DMT, and LSD are demonstrating significant potential…...

EdClinical
clinicalleader.com > doc > redefining-vaccine-trial-recruitment-accommodating-subject-diversity-with-a-transparent-data-driven-approach-0001

Redefining Vaccine Trial Recruitment - Accommodating Subject Diversity With A Transparent, Data-Driven Approach

1+ week, 5+ day ago   (116+ words) Redefining Vaccine Trial Recruitment - Accommodating Subject Diversity With A Transparent Data-Driven Approach Clinical Leader Redefining Vaccine Trial Recruitment - Accommodating Subject Diversity With A Transparent, Data-Driven Approach Post-pandemic recruitment is broken, and over 80% of drug studies are paying the price in…...